bClostridium difficile is a leading cause of health care-associated diarrhea with significant morbidity and mortality, and new options for the treatment of C. difficile-associated diarrhea (CDAD) are needed. Cadazolid is a new oxazolidinone-type antibiotic that is currently in clinical development for treatment of CDAD. Here, we report the in vitro and in vivo antibacterial evaluation of cadazolid against C. difficile. Cadazolid showed potent in vitro activity against C. difficile with a MIC range of 0.125 to 0.5 g/ml, including strains resistant to linezolid and fluoroquinolones. In time-kill kinetics experiments, cadazolid showed a bactericidal effect against C. difficile isolates, with >99.9% killing in 24 h, and was more bactericidal than vancomycin. In contrast to metronidazole and vancomycin, cadazolid strongly inhibited de novo toxin A and B formation in stationary-phase cultures of toxigenic C. difficile. Cadazolid also inhibited C. difficile spore formation substantially at growth-inhibitory concentrations. In the hamster and mouse models for CDAD, cadazolid was active, conferring full protection from diarrhea and death with a potency similar to that of vancomycin. These findings support further investigations of cadazolid for the treatment of CDAD.C lostridium difficile infection (CDI), or CDAD for C. difficileassociated diarrhea, is a major health care problem and a leading cause of morbidity and mortality in elderly hospitalized patients (1, 2). During the past decade, there has been a renewed interest in CDAD triggered by an increase in both frequency and severity of the disease in the Western world and the discovery of new hypervirulent strains (3-6), as well as an increased incidence of CDAD in the community (7). CDAD results from overgrowth of toxin-producing strains in the colon, typically following disturbances of the normal protective enteric flora. Clinical symptoms range from asymptomatic colonization to diarrhea, severe pseudomembranous colitis, sepsis, and death. The main virulence factors of C. difficile are two high-molecular-weight toxins, the enterotoxin toxin A (TcdA) and the cytotoxin toxin B (TcdB), while the contribution of the binary toxin remains unclear (8). Toxin A and toxin B cause damage to the intestinal epithelial barrier and promote mucosal inflammation. In fact, the main clinical symptoms of CDAD (secretory diarrhea and inflammation of the colonic mucosa) can be explained by the action of toxins A and B (8). Moreover, C. difficile produces endospores that are resistant to antibiotic treatment and routine disinfection (9). Spores surviving in the gut of patients and in the hospital environment may play a major role in reinfection and relapse of CDAD. Current antibiotic therapy for CDAD includes vancomycin and metronidazole, which have limited treatment success in severe disease, and high recurrence rates of up to 30% have been observed with these treatments (10). Only one new antibiotic, fidaxomicin (11, 12), has been approved in the last 30 years for this indication. In c...